Form 4: Kura Oncology CSO Granted 185,000 Stock Options

Kura Oncology's Chief Scientific Officer, Francis Burrows, was granted 185,000 stock options with an exercise price of $10.335.

Summary

• Francis Burrows, Chief Scientific Officer of Kura Oncology, Inc. (KURA), was granted 185,000 options to purchase common stock.
• The options have an exercise price of $10.335 per share.
• The grant date for these options was January 2, 2026.
• The options will vest in 48 equal monthly installments, commencing on the grant date.
• The expiration date for these options is January 1, 2036.
• Following this transaction, Francis Burrows beneficially owns 185,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a standard compensation event that aligns management's interests with shareholder value creation, generally viewed as a neutral to slightly positive development.

Positives

• The grant of stock options aligns the Chief Scientific Officer's financial interests with the long-term performance and shareholder value creation of Kura Oncology.

Future Outlook

The options are subject to a vesting schedule of 48 equal monthly installments commencing on the grant date, indicating a long-term incentive structure.

Industry Context

This transaction represents a standard executive compensation practice within the biotechnology industry, where stock options are commonly used to incentivize key personnel and align their performance with shareholder interests.

Comparison to Industry Standards

• Granting stock options to executive officers is a common practice in the biotechnology sector, aligning management incentives with shareholder value.
• The vesting schedule (48 equal monthly installments) and exercise price ($10.335) are consistent with typical executive incentive plans in the life sciences industry.

Related Party Transactions

• The grant of stock options to Francis Burrows, the Chief Scientific Officer, constitutes a related-party transaction as it involves compensation from the company to an executive officer.

Stakeholder Impact

• Shareholders: The option grant aims to align the Chief Scientific Officer's long-term interests with shareholder value creation, potentially leading to improved performance and stock appreciation.
• Employees: This reflects the company's compensation strategy for its executive team, which can influence overall employee morale and retention strategies.

Next Steps

• The options will vest in 48 equal monthly installments, commencing on January 2, 2026.

Key Dates

Keywords

Kura Oncology, KURA, stock options, executive compensation, insider transaction, Form 4, Francis Burrows, Chief Scientific Officer, biotechnology